Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)(BRIDGE) | completed | Phase 2 | 86 | Technische Universität DresdenOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT00134004 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Oct 6, 2015 |
| clinicaltrials |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 31 | BiogenINDUSTRY | 1 | Oct 2, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT01625741 | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy(HYDRIC) | terminated | Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00324779 | Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia | completed | Phase 2 | 79 | University Hospital ErlangenOTHER | 2 | Sep 25, 2015 | clinicaltrials |
| NCT00435084 | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL | completed | Phase 1 / Phase 2 | 10 | Valerio TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT02502968 | BL-8040 Addition to Consolidation Therapy in AML Patients(BLAST) | unknown | Phase 2 | 194 | Dr. Petra TschanterOTHER | 1 | Sep 21, 2015 | clinicaltrials |
| NCT00038610 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | completed | Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2015 | clinicaltrials |
| NCT00609869 | Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT01802450 | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase(DASAPOST) | unknown | Phase 2 | 18 | PETHEMA FoundationOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02338050 | Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 1 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 16, 2015 | clinicaltrials |
| NCT00866736 | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia | completed | Phase 2 | 65 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT01342679 | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib(CMR-CML) | completed | Phase 2 | 21 | Kanto CML Study GroupOTHER | 1 | Sep 15, 2015 | clinicaltrials |
| NCT00632749 | BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | completed | Phase 2 | 68 | Boehringer IngelheimINDUSTRY | 1 | Sep 14, 2015 | clinicaltrials |
| NCT02544789 | Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia | completed | Phase 2 | 44 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 9, 2015 | clinicaltrials |
| NCT00844298 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 91 | Asan Medical CenterOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT01016600 | Azacitidine and Lenalidomide for Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 31 | Washington University School of MedicineOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00759603 | Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00446173 | Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT00004040 | Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy | withdrawn | Phase 2 | 0 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | completed | Phase 2 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01563055 | A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 10 | GlaxoSmithKlineINDUSTRY | 1 | Aug 10, 2015 | clinicaltrials |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT02511340 | A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients | unknown | Phase 2 | 167 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 30, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00045513 | Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00533078 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies(LUNCH1) | completed | Phase 2 | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2015 | clinicaltrials |
| NCT00274781 | Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 2 | 30 | The Cleveland ClinicOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(ALLPhi) | terminated | Phase 1 / Phase 2 | 8 | Rony SchaffelOTHER | 0 | Jul 9, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
| NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible(TCP-AML) | unknown | Phase 1 / Phase 2 | 16 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00431873 | A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 21 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00905034 | Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL(PCYC-1109-CA) | completed | Phase 1 / Phase 2 | 71 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01126814 | A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 35 | University Health Network, TorontoOTHER | 1 | Jun 24, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Oct 7, 2015source: clinicaltrials